Anaphylaxis to Oral Trimethoprim-Sulfamethoxazole in a Child: A Case Report

Haruna Mabuchi1,2, Naoki Kajita1, Go Kusakawa1

  • 1Division of Allergy, Tokyo Metropolitan Children's Medical Center, Fuchu, JPN.

Cureus
|March 24, 2025
PubMed

Insights

Anaphylaxis to trimethoprim-sulfamethoxazole (TMP-SMX) is rare but possible in children. A basophil activation test (BAT) showed promise as a safer diagnostic tool than drug provocation tests (DPT) for TMP-SMX allergy.

Area of Science:

  • Pediatric Allergy and Immunology
  • Clinical Pharmacology
  • Drug Hypersensitivity

Background:

  • Trimethoprim-sulfamethoxazole (TMP-SMX) is a widely used antibiotic in pediatric care for treating infections and prophylaxis.
  • While typically associated with non-immediate hypersensitivity, immediate reactions like anaphylaxis are uncommon.

Observation:

  • A case report describes a 6-year-old girl who experienced anaphylaxis following TMP-SMX administration.
  • Standard skin prick testing with TMP-SMX yielded negative results.
  • The patient developed anaphylaxis during a drug provocation test (DPT).

Findings:

  • A basophil activation test (BAT) performed on the patient for the TMP-SMX combination was positive.
  • This suggests BAT may be a viable diagnostic method for TMP-SMX allergy.
  • The positive BAT contrasts with the negative skin prick test, highlighting potential diagnostic limitations of traditional methods.

Implications:

  • This case highlights the importance of considering alternative diagnostic strategies for drug hypersensitivity when conventional tests are inconclusive or high-risk.
  • Basophil activation testing (BAT) may offer a safer and more sensitive approach for diagnosing TMP-SMX allergy in pediatric patients.
  • Further research is warranted to validate the utility and reliability of BAT for TMP-SMX allergy diagnosis in broader populations.